CTI Biopharma Corp represents values of innovation, dedication, and commitment to improving patients' lives. With a focus on developing transformative therapies, CTI Biopharma Corp aims to address unmet medical needs and advance the field of oncology. The company embraces a patient-centric approach, driven by a strong corporate philosophy that places integrity, excellence, and collaboration at its core. CTI Biopharma Corp's ongoing research and development efforts aim to make significant advancements in the treatment of blood-related cancers. Through its innovative pipeline and strategic partnerships, the company is dedicated to making a positive impact on the healthcare industry and ultimately improving patient outcomes.

CTI Biopharma Corp is primarily present in the United States.

CTI Biopharma Corp has achieved several significant milestones. Firstly, the company successfully obtained FDA approval for its product Pixuvri®, a treatment for adult patients with a certain type of non-Hodgkin lymphoma. Additionally, CTI Biopharma Corp has received FDA Fast Track designation for pacritinib, an investigational treatment for patients with myelofibrosis. The company also entered into a licensing agreement with Baxter International Inc. for rights to commercialize Pixuvri® in certain territories. Furthermore, CTI Biopharma Corp has made progress in advancing its pipeline, with ongoing clinical trials focusing on the development of innovative treatments in various therapeutic areas. Overall, the company's achievements highlight its commitment to delivering novel therapies for the benefit of patients.

CTI Biopharma Corp, a leading biopharmaceutical company, has a rich history and background. Established in 1991 and headquartered in Seattle, Washington, CTI focuses on developing novel therapies for blood-related cancers. The company initially operated under the name Cell Therapeutics, Inc., and rebranded as CTI Biopharma Corp in 2014. With a strong emphasis on research and innovation, CTI has made significant strides in cancer treatment, particularly in areas like stem cell transplant and small molecule drug development. Today, CTI Biopharma Corp continues to be a renowned player in the biopharmaceutical industry, committed to advancing cutting-edge therapies for patients around the world.

The main competitors of CTI Biopharma Corp in the market are Jazz Pharmaceuticals, Inc., Incyte Corporation, and Celgene Corporation.

CTI Biopharma Corp is primarily active in the biopharmaceutical industry.

The business model of CTI Biopharma Corp focuses on developing and commercializing novel targeted therapies for blood-related cancers. They specialize in research, development, and marketing of treatments that aim to improve the lives of patients with hematologic malignancies. Through innovative drug discovery and clinical trials, CTI Biopharma Corp aims to address unmet medical needs in the oncology field. With a strong emphasis on scientific advancements, the company strives to bring new treatment options to patients worldwide.

مُعامل القيمة السوقية إلى الأرباح لـ CTI Biopharma هو ١٣٫٦٣.

مُعامِل القيمة إلى المبيعات CTI Biopharma هو ٣٫٠٢.

نقاط جودة AlleAktien لـ CTI Biopharma هي 5/10.

المتوقعة CTI Biopharma الإيرادات هي ٣٤٥٫٥٥ مليون. USD.

صافي الربح المتوقعة CTI Biopharma هو ٧٦٫٥١ مليون. USD.

CTI Biopharma Corp is a global company in the biopharmaceutical industry that specializes in the research, development, production, and marketing of innovative cancer therapies. The company is headquartered in Seattle, USA, and has continuously grown since its founding in 1991. CTI Biopharma Corp's business model is based on the research and development of new cancer therapies that target signaling pathways in tumor cells. The company utilizes advanced technologies such as protein engineering and hemato-oncology technology to identify and optimize new compounds. One of CTI Biopharma Corp's developed substances is Pacritinib, an inhibitor of JAK2 and FLT3 for the treatment of blood cancer. The medication is considered a potential alternative for patients who do not respond sufficiently to other drugs. Other therapeutics in advanced stages of development include Pracinostat, an HDAC inhibitor therapy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as Resminostat, another HDAC inhibitor for the treatment of gastrointestinal tumors. CTI Biopharma Corp has its own research department and collaborations with leading scientific institutions and research organizations worldwide. This enables the company to effectively and timely advance the research and development of new therapies. Another important aspect of CTI Biopharma Corp's business model is cooperation with other companies and organizations in the biopharmaceutical industry. This involves the marketing and distribution of products as well as the exploration of new therapy areas. Overall, CTI Biopharma Corp's business model is focused on the long-term development and marketing of innovative cancer therapies. The company relies on close collaboration with scientific institutions, effective research and development processes, targeted marketing, and partnerships with other companies in the industry. Through this strategy, CTI Biopharma Corp is able to achieve and maintain continuous growth and a strong position in the cancer therapy market in the long run.

يوزع CTI Biopharma أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ CTI Biopharma في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـCTI Biopharma هو US12648L6011.

رمز WKN لـ CTI Biopharma هو A2DJWX.

الرمز المُختصر لـ CTI Biopharma هو CTIC.

خلال آخر 12 شهراً، دفعت CTI Biopharma توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع CTI Biopharma خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ CTI Biopharma هي .

CTI Biopharma يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

CTI Biopharma دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

CTI Biopharma يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من CTI Biopharma المُعلن عنها في ٢٩‏/٧‏/٢٠٢٥، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٩‏/٧‏/٢٠٢٥.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٩‏/٧‏/٢٠٢٥.

في العام 2024، وزعت CTI Biopharma 0 USD كأرباح أسهم.

يتم توزيع أرباح CTI Biopharma بالعملة USD.